Display options
Share it on
Full text links

Eur J Clin Pharmacol. 1978 Jul 30;13(5):331-44. doi: 10.1007/BF00644604.

Oral antipyretic therapy: evaluation of the N-aryl-anthranilic acid derivatives mefenamic acid, tolfenamic acid and flufenamic acid.

European journal of clinical pharmacology

S Keinänen, S Similä, K Kouvalainen

PMID: 668793 DOI: 10.1007/BF00644604


The antipyretic activity of three N-aryl-anthranilic acid derivatives, mefenamic acid, tolfenamic acid and flufenamic acid, was compared and their optimal antipyretic dose determined in a trial in 87 children (aged 5 months to 15 years), who suffered from infections and fever exceeding 38.5 degrees C. Tolfenamic acid proved to be the most potent antipyretic agent of the three drugs; it was eight times more powerful than mefenamic acid and three times more powerful than flufenamic acid. The optimal antipyretic doses were: mefenamic acid 4 mg/kg, tolfenamic acid 0.5 mg/kg and flufenamic acid 1.5 mg/kg. It is evident that the antipyretic activity of these anthranilic acid derivatives is even greater than their antirheumatic effect, the difference being most noticeable in the case of tolfenamic acid.

Similar articles

Show all 110 similar articles

Cited by


  1. Pharmacol Rev. 1974 Mar;26(1):33-67 - PubMed
  2. J Pediatr. 1968 Jun;72(6):867-70 - PubMed
  3. Nat New Biol. 1972 Jul 26;238(82):104-6 - PubMed
  4. Scand J Rheumatol. 1976;5(3):129-32 - PubMed
  5. Arzneimittelforschung. 1977;27(3):687-8 - PubMed
  6. Ann Phys Med. 1966 May;8(6):208-13 - PubMed
  7. Ann Rheum Dis. 1967 Nov;26(6):494-8 - PubMed
  8. Scand J Rheumatol. 1972;1(2):91-3 - PubMed
  9. Scand J Rheumatol Suppl. 1975;10:1-6 - PubMed
  10. Nature. 1972 Dec 15;240(5381):410-1 - PubMed
  11. Scand J Rheumatol. 1976;5(2):81-3 - PubMed
  12. Arzneimittelforschung. 1975 Jul;25(7):1082-5 - PubMed
  13. Nat New Biol. 1971 Jun 23;231(25):232-5 - PubMed
  14. Biochem Pharmacol. 1974 May 15;23(10):1439-50 - PubMed


MeSH terms

Publication Types

LinkOut - more resources